Goldman Sachs’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-9,000
Closed -$1.62M 6950
2017
Q3
$1.62M Sell
9,000
-9,600
-52% -$1.34M ﹤0.01% 4161
2017
Q2
$1.93M Buy
18,600
+4,100
+28% +$335K ﹤0.01% 3871
2017
Q1
$1.14M Buy
14,500
+11,300
+353% +$699K ﹤0.01% 4256
2016
Q4
$143K Sell
3,200
-275,600
-99% -$13.5M ﹤0.01% 5969
2016
Q3
$15.6M Buy
278,800
+269,000
+2,745% +$15M ﹤0.01% 2087
2016
Q2
$490K Sell
9,800
-34,600
-78% -$1.7M ﹤0.01% 4871
2016
Q1
$2.04M Sell
44,400
-3,800
-8% -$184K ﹤0.01% 3448
2015
Q4
$2.97M Sell
48,200
-12,000
-20% -$845K ﹤0.01% 3288
2015
Q3
$3.35M Buy
60,200
+22,200
+58% +$1.4M ﹤0.01% 3268
2015
Q2
$2.32M Buy
38,000
+31,900
+523% +$1.82M ﹤0.01% 3696
2015
Q1
$352K Buy
+6,100
New +$409K ﹤0.01% 5493

Goldman Sachs's KITE Position: Q4 2017 in Review

Goldman Sachs sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 806,480 shares — an estimated $145M sold.

Goldman Sachs first reported a position in KITE in Q1 2015 and held it in 11 quarters. The position peaked at $145M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Goldman Sachs reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 806,480 Kite Pharma, Inc. shares in Q4 2017, an estimated $145M.
  • Goldman Sachs first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 11 quarters.
  • Goldman Sachs's Kite Pharma, Inc. position peaked at $145M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.